newsfilter
← Latest News
Business Wire·

LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation

XOMA acquires future milestone economics and royalties associated with arimoclomol and aldoxorubicin, allowing LadRx to focus on core LADR assets LadRx Corporation (OTCQB:LADX) ("LadRx" or the